stockrowLeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) Revenue
LeMaitre Vascular, Inc.'s revenue for fiscal 2025 was $249.6M, up 13.5% from $219.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $269.4M. Over the past ten years it has ranged from $78.4M (fiscal 2015) to $249.6M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. LeMaitre Vascular, Inc. ranks 28th of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $249.6M | 13.53% |
| FY2024 | $219.9M | 13.63% |
| FY2023 | $193.5M | 19.69% |
| FY2022 | $161.7M | 4.68% |
| FY2021 | $154.4M | 19.37% |
| FY2020 | $129.4M | 10.35% |
| FY2019 | $117.2M | 11.05% |
| FY2018 | $105.6M | 4.66% |
| FY2017 | $100.9M | 13.14% |
| FY2016 | $89.2M | 13.78% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $68.0M | (3.43%) |
| Jun 2026 | $70.4M | 5.76% |
| Mar 2026 | $66.6M | 3.26% |
| Dec 2025 | $64.5M | 5.58% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | $3.6B |
| STVN Stevanato Group S.p.A. compare | $1.4B |
| WRBY Warby Parker Inc. compare | $934.7M |
| AZTA Azenta, Inc. compare | $613.8M |
| ATRC AtriCure, Inc. compare | $589.8M |
| STAA STAAR Surgical Company compare | $328.3M |
| LMAT LeMaitre Vascular, Inc. | $269.4M |
| KMTS Kestra Medical Technologies, Ltd. compare | $106.7M |
| PLSE Pulse Biosciences, Inc compare | $1.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LMAT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement